Journal
BIOMEDICINES
Volume 9, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9030249
Keywords
drug repurposing; induced fit; molecular dynamics simulation; xeroderma pigmentosum complementation group D; ATP binding; 4E1RCat; nucleotide excision repair
Categories
Funding
- Japanese Ministry of Health and Welfare [36, 20FC1043]
- Research on Measures for Intractable Diseases from the Japan Agency for Medical Research and Development [16ek0109028h0003, DNW-17005]
- MEXT/JSPS [18K07414, 19K07867, 19K012202]
- Grants-in-Aid for Scientific Research [19K07867, 18K07414] Funding Source: KAKEN
Ask authors/readers for more resources
XPD, a rare genetic disease, was successfully treated with the candidate drug 4E1RCat, demonstrating in silico drug repurposing as a cost-effective approach for drug candidate discovery.
Xeroderma pigmentosum complementation group D (XPD) is a UV-sensitive syndrome and a rare incurable genetic disease which is caused by the genetic mutation of the excision repair cross-complementation group 2 gene (ERCC2). Patients who harbor only XPD R683W mutant protein develop severe photosensitivity and progressive neurological symptoms. Cultured cells derived from patients with XPD (XPD R683W cells) demonstrate a reduced nucleotide excision repair (NER) ability. We hope to ameliorate clinical symptoms if we can identify candidate agents that would aid recovery of the cells' NER ability. To investigate such candidates, we created in silico methods of drug repurposing (in silico DR), a strategy that utilizes the recovery of ATP-binding in the XPD R683W protein after the induced fit. We chose 4E1RCat and aprepitant as the candidates for our in silico DR, and evaluated them by using the UV-induced unscheduled DNA synthesis (UDS) assay to verify the recovery of NER in XPD R683W cells. UDS values of the cells improved about 1.4-1.7 times after 4E1RCat treatment compared with solvent-only controls; aprepitant showed no positive effect. In this study, therefore, we succeeded in finding the candidate agent 4E1RCat for XPD R683W. We also demonstrated that our in silico DR method is a cost-effective approach for drug candidate discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available